197 related articles for article (PubMed ID: 22644942)
1. Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.
Krishnan B; Smith TL; Dubey P; Zapadka ME; Torti FM; Willingham MC; Tallant EA; Gallagher PE
Prostate; 2013 Jan; 73(1):71-82. PubMed ID: 22644942
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.
Krishnan B; Torti FM; Gallagher PE; Tallant EA
Prostate; 2013 Jan; 73(1):60-70. PubMed ID: 22644934
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2.
Menon J; Soto-Pantoja DR; Callahan MF; Cline JM; Ferrario CM; Tallant EA; Gallagher PE
Cancer Res; 2007 Mar; 67(6):2809-15. PubMed ID: 17363603
[TBL] [Abstract][Full Text] [Related]
4. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor.
Soto-Pantoja DR; Menon J; Gallagher PE; Tallant EA
Mol Cancer Ther; 2009 Jun; 8(6):1676-83. PubMed ID: 19509262
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-(1-7) reverses angiogenic dysfunction in corpus cavernosum by acting on the microvasculature and bone marrow-derived cells in diabetes.
Singh N; Vasam G; Pawar R; Jarajapu YP
J Sex Med; 2014 Sep; 11(9):2153-63. PubMed ID: 24953642
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
Nemeth JA; Yousif R; Herzog M; Che M; Upadhyay J; Shekarriz B; Bhagat S; Mullins C; Fridman R; Cher ML
J Natl Cancer Inst; 2002 Jan; 94(1):17-25. PubMed ID: 11773278
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-(1-7) Decreases Cell Growth and Angiogenesis of Human Nasopharyngeal Carcinoma Xenografts.
Pei N; Wan R; Chen X; Li A; Zhang Y; Li J; Du H; Chen B; Wei W; Qi Y; Zhang Y; Katovich MJ; Sumners C; Zheng H; Li H
Mol Cancer Ther; 2016 Jan; 15(1):37-47. PubMed ID: 26671566
[TBL] [Abstract][Full Text] [Related]
9. Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: involvement in osteoblastogenesis and osteoclastogenesis.
Yamaguchi M; Zhu S; Zhang S; Wu D; Moore TM; Snyder JP; Shoji M
Cell Tissue Res; 2014 Jul; 357(1):245-52. PubMed ID: 24723227
[TBL] [Abstract][Full Text] [Related]
10. Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling.
Mancini A; Colapietro A; Pompili S; Del Fattore A; Delle Monache S; Biordi LA; Angelucci A; Mattei V; Liang C; Gravina GL; Festuccia C
Tumour Biol; 2018 Apr; 40(4):1010428318771773. PubMed ID: 29687745
[TBL] [Abstract][Full Text] [Related]
11. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
12. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells.
Bhatia V; Saini MK; Shen X; Bi LX; Qiu S; Weigel NL; Falzon M
Mol Cancer Ther; 2009 Jul; 8(7):1787-98. PubMed ID: 19584236
[TBL] [Abstract][Full Text] [Related]
13. Pre-treatment with angiotensin-(1-7) inhibits tumor growth via autophagy by downregulating PI3K/Akt/mTOR signaling in human nasopharyngeal carcinoma xenografts.
Lin YT; Wang HC; Chuang HC; Hsu YC; Yang MY; Chien CY
J Mol Med (Berl); 2018 Dec; 96(12):1407-1418. PubMed ID: 30374682
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human lung cancer cell growth by angiotensin-(1-7).
Gallagher PE; Tallant EA
Carcinogenesis; 2004 Nov; 25(11):2045-52. PubMed ID: 15284177
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
[TBL] [Abstract][Full Text] [Related]
16. Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis.
Takemori T; Kawamoto T; Ueha T; Toda M; Morishita M; Kamata E; Fukase N; Hara H; Fujiwara S; Niikura T; Kuroda R; Akisue T
Oncol Rep; 2018 Oct; 40(4):2079-2087. PubMed ID: 30066936
[TBL] [Abstract][Full Text] [Related]
17. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
18. Pristimerin Inhibits Prostate Cancer Bone Metastasis by Targeting PC-3 Stem Cell Characteristics and VEGF-Induced Vasculogenesis of BM-EPCs.
Huang S; He P; Peng X; Li J; Xu D; Tang Y
Cell Physiol Biochem; 2015; 37(1):253-68. PubMed ID: 26302893
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
20. Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer.
van der Horst G; van den Hoogen C; Buijs JT; Cheung H; Bloys H; Pelger RC; Lorenzon G; Heckmann B; Feyen J; Pujuguet P; Blanque R; Clément-Lacroix P; van der Pluijm G
Neoplasia; 2011 Jun; 13(6):516-25. PubMed ID: 21677875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
